Document detail
ID

doi:10.1007/s00280-023-04548-1...

Author
König, Philipp Zhulenko, Roman Suparman, Eloy Hoffmeister, Henrik Bückreiß, Nico Ott, Ingo Bendas, Gerd
Langue
en
Editor

Springer

Category

Medicine & Public Health

Year

2023

listing date

6/7/2023

Keywords
cisplatin chemoresistance erk-signaling gold(i)-nhc-complex ovarian cancer thioredoxin reductase a2780cis ovarian cancer auranofin nhc-au -compounds mc3 balance cell redox cisplatin resistance
Metrics

Abstract

Purpose Cisplatin resistance is the major obstacle in the clinical treatment of ovarian cancer patients.

Molecular mechanisms of cisplatin resistance are multifaceted.

Gold(I)-compounds, i.e. N -heterocyclic carbene-gold(I)-complexes (NHC-Au(I)) has been regarded as promising cytotoxic drug candidates.

However, their potential to overcome cisplatin resistance has hardly been addressed yet.

Here we investigated the activity of the gold(I) drug auranofin and the NHC-Au(I)-compound MC3 in W1CR and A2780cis cisplatin-resistant ovarian cancer cells.

Methods Cytotoxicity of auranofin and MC3 was detected by MTT assay, correlated with intracellular gold(I) content, analyzed by AAS, and with flow cytometric detection of the cell cycle.

Insight into cellular redox balance was provided by fluorimetric ROS-formation assay and western blotting thioredoxin (Trx) and Nrf2.

The role of ERK was elucidated by using the inhibitor SCH772984 and its impact on cytotoxicity upon co-treatment with cisplatin and Au(I)-compounds, respectively.

Results MC3 overcomes cisplatin resistance in A2780cis and W1CR, and auranofin in W1CR cells completely, which is neither reflected by intracellular gold levels nor cell cycle changes.

Upregulated redox balance appears as a basis for resistance.

W1CR cells possess higher Trx levels, whereas A2780cis cells display strong Nrf2 expression as anti-oxidative protection.

Nevertheless, overcoming redox balance appears not primary mode of activity comparing cisplatin and gold(I)-compounds.

pERK emerges as a critical component and thus a promising target for overcoming resistance, regulating apoptosis differently in response to either gold(I) or cisplatin in A2780 cells.

Conclusion These data reflect the complexity of cisplatin resistance in cell models and emphasize NHC-Au(I)-complexes as prospective cytotoxic agents for further investigations in that respect.

König, Philipp,Zhulenko, Roman,Suparman, Eloy,Hoffmeister, Henrik,Bückreiß, Nico,Ott, Ingo,Bendas, Gerd, 2023, A biscarbene gold(I)-NHC-complex overcomes cisplatin-resistance in A2780 and W1 ovarian cancer cells highlighting pERK as regulator of apoptosis, Springer

Document

Open

Share

Source

Articles recommended by ES/IODE AI

Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
gravis myasthenia study clinical phase baseline improvement mg-adl 340 week trial placebo period mg maintenance qw